Home › Acute Myeloid Leukemia › Washington
Acute Myeloid Leukemia clinical trials in Washington
41 studies for Acute Myeloid Leukemia are looking for participants at sites in Washington.
Cities in Washington
- Seattle40 studies
- Spokane Valley7 studies
- Renton6 studies
- Kirkland6 studies
- Spokane4 studies
- Tacoma3 studies
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 12 to 78 · All sexes · Updated Sep 29, 2026 · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Fred Hutchinson Cancer Center, Seattle
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Fred Hutchinson Cancer Center, Seattle
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Recruiting
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07094750A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- and 1 more
RecruitingPhase 3
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07645469CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04375631A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Recruiting
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07616921Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
RecruitingPhase 3
Ages 1 to 25 · All sexes · Updated Sep 4, 2026 · NCT07022678Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- and 19 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Aug 26, 2026 · NCT06834282The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- and 1 more
RecruitingPhase 1/2
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Seattle Children's Hospital, Seattle
RecruitingPhase 3
29 Days – 21 Years · All sexes · Updated Aug 24, 2026 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Washington, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Recruiting
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT06710418Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
- Fred Hutchinson Cancer Center/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT03737955Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06529731Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Jul 22, 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT07046078A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2Healthy volunteers welcome
6 Months · All sexes · Updated May 29, 2026 · NCT04195633HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1
Up to age 80 · All sexes · Updated May 18, 2026 · NCT03326921Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT06928662A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Seattle Cancer Care Alliance, Seattle
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT04797767A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT05732103A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Fred Hutch/University of Washington Cancer Consortium, Seattle
RecruitingPhase 2
Ages 1 to 60 · All sexes · Updated Mar 12, 2026 · NCT03970096PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
- Seattle Children's Hospital, Seattle
RecruitingPhase 1
Up to age 30 · All sexes · Updated Dec 23, 2025 · NCT05105152HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 2
3 Months · All sexes · Updated Nov 12, 2025 · NCT02143830Novel Digital Application for Patients With Acute Leukemia
- Fred Hutchinson Cancer Research Center (FHCRC), Seattle
Recruiting
Ages 18 to 120 · All sexes · Updated Nov 10, 2025 · NCT06472128A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Fred Hutchinson Cancer Center, Seattle
RecruitingHealthy volunteers welcome
Ages 18 to 120 · All sexes · Updated Jul 25, 2025 · NCT05237258From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.